HCM
HZNP

Hodges Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hodges Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-69,606
Closed -$826K – 281
2017
Q2 		$826K Sell
69,606
-2,339,790
-97% -$29.1M 0.05% 178
2017
Q1 		$35.6M Buy
2,409,396
+230,905
+11% +$3.74M 1.78% 12
2016
Q4 		$35.2M Buy
2,178,491
+90,855
+4% +$1.65M 1.62% 18
2016
Q3 		$37.8M Sell
2,087,636
-100,358
-5% -$1.96M 1.82% 11
2016
Q2 		$36M Buy
2,187,994
+119,340
+6% +$1.93M 1.75% 14
2016
Q1 		$34.3M Buy
2,068,654
+496,860
+32% +$8.69M 1.58% 17
2015
Q4 		$34.1M Buy
1,571,794
+61,454
+4% +$1.2M 1.42% 17
2015
Q3 		$29.9M Sell
1,510,340
-108,734
-7% -$3.44M 1.23% 24
2015
Q2 		$56.2M Buy
1,619,074
+56,170
+4% +$1.71M 2.05% 4
2015
Q1 		$40.6M Sell
1,562,904
-117,140
-7% -$2.15M 1.55% 7
2014
Q4 		$21.7M Buy
1,680,044
+827,514
+97% +$10.4M 0.88% 44
2014
Q3 		$10.5M Buy
+852,530
New +$9.91M 0.43% 97

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Hodges Capital Management's HZNP Position: Q3 2017 in Review

Hodges Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 69,606 shares — an estimated $826K sold.

Hodges Capital Management first reported a position in HZNP in Q3 2014 and held it in 12 quarters. The position peaked at $56.2M in Q2 2015. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • Hodges Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Hodges Capital Management sold 69,606 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $826K.
  • Hodges Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 12 quarters.
  • Hodges Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $56.2M in Q2 2015.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Hodges Capital Management's 13F filing for Q3 2017, filed 2 Nov 2017.